You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

Article metrics

Article menu

Download PDFPDF

Oral Plenary
Plenary I
IGCS20_1268
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 202016021
Dec 20203905
Jan 20211603
Feb 20211705
Mar 20212005
Apr 20212108
May 2021304
Jun 2021102
Jul 2021001
Aug 2021008
Sep 2021108
Oct 202117022
Nov 202126023
Dec 20211802
Jan 20221300
Feb 20221804
Mar 2022803
Apr 20221002
May 20221208
Jun 2022907
Jul 20223103
Aug 20223005
Sep 202222010
Oct 20222205
Nov 2022801
Dec 20221603
Jan 20232203
Feb 20231500
Mar 20232001
Apr 2023603
May 2023600
Jun 2023300
Jul 20231104
Aug 20232202
Sep 2023805
Oct 2023802
Nov 202318013
Dec 20232302
Jan 20241801
Feb 20241202
Mar 202410022
Apr 2024403
Total6000231